Consensus Damora Therapeutics, Inc.

Stocks

DMRA

KYG2646Y1044

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 15:22:02 26/10/2026 GMT			5-day change	1st Jan Change
21.58 ^USD	+2.32%		+11.65%	-6.50%

09-28	Damora Therapeutics Insider Bought Shares Worth $252,875, According to a Recent SEC Filing	MT
09-20	Damora Therapeutics, Inc.(NasdaqCM:DMRA) added to S&P Global BMI Index	CI

Evolution of the Average Target: Damora Therapeutics, Inc.

Evolution of the Target Price: Damora Therapeutics, Inc.

Changes in Analyst Recommendations: Damora Therapeutics, Inc.

e2e2ceafbb5086b2b01d.85l0E5RRegPlb5-Ji8eLGe0-2biT-RMLelgHSr9L_aw.sMZCetcXEEioDavsyaHTTIgNrMr5pipyNwlBJ_EyovqD3zZE8hJJcZc-8A~d29ead499039766a5b3667782017b53a

Analysts' recommendations: Damora Therapeutics, Inc.

07-29	Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating	MT
07-27	Jefferies Initiates Coverage on Damora Therapeutics With Buy Rating, $50 Price Target	MT
06-11	HC Wainwright Initiates Damora Therapeutics at Buy With $45 Price Target	MT
06-08	TD Cowen Initiates Damora Therapeutics at Buy	MT
05-28	Wedbush Initiates Damora Therapeutics at Outperform With $35 Price Target	MT
04-24	Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says	MT
04-24	RBC Initiates Damora Therapeutics at Outperform, Speculative Risk With $40 Price Target	MT
12-01	Guggenheim Initiates Coverage on Galecto With Buy Rating, $32 Price Target	MT
10/06/24	Oppenheimer Adjusts Price Target on Galecto to $9 From $10, Maintains Outperform Rating	MT
28/09/23	HC Wainwright Downgrades Galecto to Neutral From Buy	MT
21/08/23	HC Wainwright Adjusts Price Target on Galecto to $2 From $12, Maintains Buy Rating	MT
20/06/23	Oppenheimer Initiates Coverage on Galecto With Outperform Rating, $12 Price Target	MT
17/03/23	Cantor Fitzgerald Initiates Galecto at Overweight With $16 Price Target	MT
03/08/22	SVB Securities Adjusts Galecto's Price Target to $13 from $16, Keeps Outperform Rating	MT
14/02/22	Credit Suisse Trims Galecto's Price Target to $6 from $7, Maintains Outperform Rating	MT
06/08/21	Galecto : Credit Suisse Lowers Galecto's PT to $7 from $12 on Lower Projected Sales for GB0139, Reduced Near-Term M&A Expectations; Keeps Outperform Rating	MT
16/03/21	Galecto : Credit Suisse Lowers Galecto's PT to $12 from $29 After Recommendation to End Parts of GB0139 Phase 2 Study, Keeps Outperform Rating	MT
16/03/21	Galecto : SVB Leerink Adjusts Galecto's Price Target to $16 From $27, Keeps Outperform Rating	MT
23/11/20	Galecto : Credit Suisse Initiates Coverage on Galecto With Outperform Rating, $29 Price Target	MT
23/11/20	Galecto : BofA Securities Initiates Coverage on Galecto With Buy Rating, $21 Price Target	MT
23/11/20	Galecto : SVB Leerink Starts Galecto at Outperform With $27 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	DAMORA THERAPEUTICS, INC.					+122.33%
	WUXI APPTEC CO., LTD.					+32.59%
	ARGENX SE					+28.07%
	LONZA GROUP AG					+10.26%
	IQVIA HOLDINGS INC.					+8.34%
	BEONE MEDICINES AG					+15.58%
	REVOLUTION MEDICINES, INC.					+38.17%
	CELLTRION, INC.					+38.53%
	WUXI BIOLOGICS (CAYMAN) INC.					+31.23%
	GENMAB A/S					+4.99%
	Average					+33.01%
	Weighted average by Cap.					+23.66%